Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
ImpediMed Limited announced a change in the director’s interest notice, specifically involving Ms. Janelle Delaney. The change reflects the acquisition of 268,169 ordinary shares as part of a compensation arrangement, where shares were issued in lieu of 30% of director fees for the quarter ending June 30, 2025. This adjustment in shareholding could impact the company’s governance and stakeholder interests, as it aligns director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices. The company’s primary products include bioimpedance spectroscopy devices used for the assessment and monitoring of fluid status and body composition, with a market focus on healthcare providers and patients managing conditions like lymphedema and heart failure.
Average Trading Volume: 2,702,662
Technical Sentiment Signal: Sell
Current Market Cap: A$103.4M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.